Health Technology SAMSUNG BIOLOGICS Co., Ltd. Business Summary
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Financial Highlights
Dec 2021
KRW USD Revenue 1,568.00B 1,369.24M Gross Profit 784,969.49M 685.46M Operating income 537,309.40M 469.20M Income before tax 547,429.45M 478.03M Net income 393,589.46M 343.69M EBITDA 699,098.05M 610.48M Diluted EPS 5,886.12 5.14 Dividends Per Share 0 0 Total Assets 7,970.01B 6,704.53M Total liabilities 2,978.90B 2,505.91M Total equity 4,991.10B 4,198.61M Operating cash flow 454,596.21M 396.97M Currency in KRW Currency in USD
Historical Data Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
464,629.33M
535,805.80M
701,591.85M
1,164.77B
1,568.00B
Gross Profit
122,304.94M
130,544.55M
230,536.76M
469,262.42M
784,969.49M
Operating income
65,979.40M
55,678.74M
92,084.47M
293,299.68M
537,309.40M
Income before tax
-115,994.75M
302,975.83M
82,495.19M
283,759.85M
547,429.45M
Net income
-96,972.11M
224,109.19M
202,904.09M
240,974.79M
393,589.46M
EBITDA
135,905.62M
147,129.29M
224,627.48M
436,474.55M
699,098.05M
Diluted EPS
-1,450.60
3,351.42
3,034.42
3,603.77
5,886.12
Dividends Per Share
0
0
0
0
0
Total Assets
7,183.09B
5,980.40B
5,911.62B
6,424.20B
7,970.01B
Total liabilities
3,206.64B
1,824.94B
1,557.17B
1,825.41B
2,978.90B
Total equity
3,976.45B
4,155.46B
4,354.45B
4,598.78B
4,991.10B
Operating cash flow
149,816.32M
36,787.30M
10,153.61M
202,090.02M
454,596.21M
Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
410.99M
486.86M
601.61M
987.19M
1,369.24M
Gross Profit
108.18M
118.62M
197.68M
397.71M
685.46M
Operating income
58.36M
50.59M
78.96M
248.58M
469.20M
Income before tax
-102.60M
275.30M
70.73M
240.49M
478.03M
Net income
-85.77M
203.63M
173.98M
204.23M
343.69M
EBITDA
120.21M
133.69M
192.61M
369.92M
610.48M
Diluted EPS
-1.28
3.04
2.60
3.05
5.14
Dividends Per Share
0
0
0
0
0
Total Assets
6,709.72M
5,359.74M
5,111.87M
5,913.83M
6,704.53M
Total liabilities
2,995.32M
1,635.54M
1,346.51M
1,680.39M
2,505.91M
Total equity
3,714.39M
3,724.20M
3,765.36M
4,233.43M
4,198.61M
Operating cash flow
132.52M
33.42M
8.70M
171.27M
396.97M
Valuation Measures
Dec 2021
PER 151.80 ROA 5.46% ROE 8.20% Operating margin 34.26% Profit margin 25.10%
Key executives
President, Chief Executive Officer & Director:
John Chongbo Rim
Head-Finance & Vice President:
Doyoung Heo
Managing Director & Head-Process Technology:
Yong-Ho An
Head-Compliance Support:
Hyung-Woo Moon
Executive Vice President:
Kyu-Sung Lee Shareholders
Samsung C&T Corp. (43.0%)
Samsung Electronics Co., Ltd. (31.2%)
National Pension Service of Korea (5.6%)
Invesco Advisers, Inc. (1.0%)
The Vanguard Group, Inc. (0.6%)
BlackRock Fund Advisors (0.6%)
Samsung Asset Management Co., Ltd. (0.4%)
Norges Bank Investment Management (0.2%)
Fidelity Management & Research Co. LLC (0.2%)
Mirae Asset Global Investments Co., Ltd. (0.2%)
Related Companies
Samsung Biologics America, Inc.
Samsung BioLogics Co., Ltd. ESOA
Samsung Romania
Competitors
Lonza Group AG
Wuxi Biologics (Cayman) Inc.
FUJIFILM Holdings Corp
PanGen Biotech, Inc.
EirGenix Inc
Binex Co., Ltd
Celltrion, Inc.
Bukwang Pharmaceutical Co., Ltd.
Celltrion Healthcare Co., Ltd.
Coherus BioSciences, Inc.
EPIRUS Biopharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
Kodiak Sciences, Inc.
PharmAbcine Inc.
PharmGen Science, Inc.
Prestige Biologics Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Reyon Pharmaceutical Co., Ltd.
SCM LIFESCIENCE CO., LTD
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Jan, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close